Published

14 Feb 26

Updated

03 May 26

Views

1.1k

Not Invested

Recursion PharmaceuticalsRXRX

Fair Value

US$1.97

Share price03 May

US$3.3168.0% overvalued

1Y-38.59%

7D-11.02%

Recursion Pharmaceuticals! WTH is going on?

537578

Author hasn't set their bio yet

Published

14 Feb 26

Updated

03 May 26

Views

1.1k

Not Invested

Shared on 03 May 26

Recursion Pharmaceuticals (RXRX) one day will be the Palantir of biotechnology! With the CMO transitioning out as well as the former CEO RXRX now has a chance to take off!

95 views

Shared on 11 Apr 26

I was very pessimistic about RXRX! I am now extremely optimistic and here’s why!

115 views

Shared on 02 Mar 26

As I see what RXRX did in the 4th quarter I now believe they will be the Palantir of biotechnology one day! Najat Khan the new CEO will lead this company out of the hole created by the former CEO into greatness!

133 views

Fair Value vs Share Price

US$1.97

vs US$3.3168.0% overvalued

52.8%

Revenue growth

19.5%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Recursion Pharmaceuticals

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Excellent balance sheet and slightly overvalued.

Market capUS$1.8b

PB1.7x

Estimated Growth26.7%

Dividend YieldN/A

Full analysis

CEO & management

Najat Khan

CEO

1.7yrs

CEO Tenure

A clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.